References
-
1
Aarons R, Nies A, Gal J, Hegstrand L, Molinoff P.
Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration.
J Clin Invest.
1980;
65
949-957
-
2
Barcellos Fontanella BJ.
Social anxiety and propranolol abuse: a case study.
Rev Bras Psiquiatr.
2003;
25
228-230
-
3
Bawert A, Fischer G.
Addiction – who is not affected?.
Wien Med Wochenschr.
2005;
155
549-561
-
4 DSM-IV .Manuel diagnostique et statistique des troubles mentaux. 4èmeédition. Trad. Paris, Masson 1996
-
5
Jolliet-Riant P, Tillement JP.
Drug transfer across the blood-brain barrier and improvement of brain delivery.
Fundam Clin Pharmacol.
1999;
13
16-26
-
6
Stemmelin J, Cohen C, Terranova JP. et al .
Stimulation of the beta(3)-adrenoreceptor as a novel treatment strategy for anxiety and depressive disorders.
Neuropsychopharmacology.
2008;
33(3)
574-587
-
7
Victorri-Vigneau C, Guerlais M, Jolliet P.
Abuse, dependence and withdrawal with gabapentin : first case report.
Pharmacopsychiatry.
2007;
40
43-44
-
8 http://www.dopage.com consulted on June 30, 2006
Correspondence
C. Victorri-Vigneau
Centre d'Evaluation et d'Information sur la Pharmacodependance
Service de Pharmacologie Clinique
9 quai Moncousu
44093 Nantes cedex 1
France
Telefon: +33/2/4008 40 96
eMail: Caroline.vigneau@chu-nantes.fr
